Mounika Darna, Pulla Sai Satya Sri, Sule Swapnil Anil, Alli Vidya Jyothi, Jadav Surender Singh
Department of Natural Products and Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Uppal Road, Hydrabad, 500037, India.
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
Anticancer Agents Med Chem. 2025;25(17):1273-1286. doi: 10.2174/0118715206356253241223040825.
Colorectal cancer (CRC) is a malignant gastrointestinal tract disorder with high occurrence and mortality index and showing an upsurge. Standard therapies for treating CRC are surgery and chemotherapy. Despite great effort in developing effective treatments, the progress is limited due to its relapse and recurrence. Prognosis of metastatic CRC is always complicated. This condition can be evaded by a novel approach i.e., targeted therapy which increases the survival rate in CRC patients by blocking important pathways and acting on immune checkpoints. Drugs with N-acyl hydrazones (NAH) are currently being employed treatment of infectious diseases and disorders. NAH in combination with diverse heterocycles, natural product isolates are identified as interesting CRC inhibitors under-explored. This review provides an overview of the existing CRC targeted compounds having acyl hydrazones, hydrazine, hydrazides moieties, and their underlying mechanisms towards different CRC cell lines, together with a discussion of their limitations and future trends.
结直肠癌（CRC）是一种恶性胃肠道疾病，其发病率和死亡率较高且呈上升趋势。治疗CRC的标准疗法是手术和化疗。尽管在开发有效治疗方法方面付出了巨大努力，但由于其复发和再发，进展有限。转移性CRC的预后总是很复杂。一种新的方法，即靶向治疗，可以避免这种情况，靶向治疗通过阻断重要途径和作用于免疫检查点来提高CRC患者的生存率。含N-酰腙（NAH）的药物目前正用于治疗传染病和疾病。NAH与多种杂环、天然产物分离物结合，被确定为有待深入研究的有趣的CRC抑制剂。本综述概述了现有的具有酰腙、肼、酰肼部分的CRC靶向化合物，以及它们对不同CRC细胞系的潜在作用机制，并讨论了它们的局限性和未来趋势。
